As a result of this acquisition, Volpara will be able to expand its product portfolio and apply its extensive experience in artificial intelligence (AI) and machine learning (ML) to revolutionize personalized breast care through new technology development. The combination of MRS and Volpara will give breast care providers a unique view of the patient journey, through screening, diagnosis and treatment. The combination of technology and data, leveraging Volpara’s deep understanding of patient and data privacy under ISO 27001 and GDPR, will enable customers to deliver personalized care, comply with regulations, and explore business and workflow improvement opportunities.
“Working in the breast health care industry with MRS for many years, we have been extremely impressed with the quality of the people and the products they build,” said Dr. Ralph Highnam, Volpara CEO. “I’m happy to announce that we are combining to create a world-class entity with a strong US customer base and an extended range of integrated products which can help detect breast cancer earlier and get accurate results to patients and their physicians faster.”
Volpara Health Technologies Limited is a leading provider of breast imaging analytics products that improve clinical decision-making and the early detection of breast cancer. Volpara software products, which are compatible with popular mammography systems from GE Healthcare, Hologic, Siemens and Fujifilm, help clinicians better understand their patients and administrators better understand their practices.
MRS has provided comprehensive patient tracking, communication, and a radiology reporting platform for sub-specialty radiology applications including breast and lung imaging for more than 25 years.
“The MRS team is delighted to be joining forces with Volpara in advancing personalized breast care,” said Mark Morris, CEO of MRS. “Our team remains committed to helping our customers better serve patients by delivering innovative products. Becoming part of Volpara will help us deliver on that promise.”